Developer of therapeutic products for cancer. The company is focused on the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Merger/Acquisition | 05-Sep-2001 | $17.7M | 000.00 | 000.00 | Completed | Clinical Trials - Phase 2 |
2. Early Stage VC | 11-Dec-1997 | 000.00 | 000.00 | Completed | Product Development | |
1. Early Stage VC | $3.8M | $3.8M | Completed |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-3292499-A | Prostate cancer drug screening | Withdrawn | 12-Feb-1998 | 0000000000 | |
EP-0844888-A4 | Tissue specific viral vectors | Granted | 27-Jun-1995 | 000000000 | 0 |
ES-2242196-T3 | Adenoviral vectors understanding an "element response". | Expired - Lifetime | 27-Jun-1995 | 000000000 | |
JP-4117347-B2 | Tissue-specific virus vector | Expired - Fee Related | 27-Jun-1995 | 000000000 | |
EP-0844888-B1 | Adenovirus vectors comprising a prostate specific antigen (psa) response element | Expired - Lifetime | 27-Jun-1995 | C12N15/86 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
AmBex Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Genesis Merchant Partners | Lender/Debt Provider | Minority | 000 0000 | 000000 0 | |
Perseus (Bethesda) | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Sequoia Capital | Venture Capital | Minority | 000 0000 | 000000 0 |